HOLX Hologic Inc

Price (delayed)

$73.94

Market cap

$18.59B

P/E Ratio

10.16

Dividend/share

N/A

EPS

$7.28

Enterprise value

$20.47B

Hologic, Inc. is a medical technology company primarily focused on women’s health; it sells medical devices for diagnostics, surgery, and medical imaging. In late November 2013, activist investor Carl Icahn ...

Highlights
HOLX's equity has surged by 56% year-on-year and by 9% since the previous quarter
The revenue has grown by 49% YoY
The EPS has surged by 72% year-on-year but it has declined by 7% since the previous quarter
The gross profit has soared by 70% YoY but it has contracted by 2.7% from the previous quarter

Key stats

What are the main financial stats of HOLX
Market
Shares outstanding
251.42M
Market cap
$18.59B
Enterprise value
$20.47B
Valuations
Price to earnings (P/E)
10.16
Price to book (P/B)
4.44
Price to sales (P/S)
3.37
EV/EBIT
8.33
EV/EBITDA
7.15
EV/Sales
3.63
Earnings
Revenue
$5.63B
EBIT
$2.46B
EBITDA
$2.86B
Free cash flow
$2.17B
Per share
EPS
$7.28
Free cash flow per share
$8.43
Book value per share
$16.64
Revenue per share
$21.91
TBVPS
$15.48
Balance sheet
Total assets
$8.92B
Total liabilities
$4.7B
Debt
$3.05B
Equity
$4.22B
Working capital
$1.84B
Liquidity
Debt to equity
0.72
Current ratio
2.39
Quick ratio
1.59
Net debt/EBITDA
0.66
Margins
EBITDA margin
50.8%
Gross margin
67.4%
Net margin
33.2%
Operating margin
43.9%
Efficiency
Return on assets
22.6%
Return on equity
49.4%
Return on invested capital
54.4%
Return on capital employed
32.4%
Return on sales
43.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HOLX stock price

How has the Hologic stock price performed over time
Intraday
0.23%
1 week
-3.76%
1 month
2.25%
1 year
2%
YTD
1.52%
QTD
0.18%

Financial performance

How have Hologic's revenue and profit performed over time
Revenue
$5.63B
Gross profit
$3.8B
Operating income
$2.47B
Net income
$1.87B
Gross margin
67.4%
Net margin
33.2%
Hologic's operating income has surged by 124% YoY but it has decreased by 7% QoQ
The gross profit has soared by 70% YoY but it has contracted by 2.7% from the previous quarter
Hologic's net income has surged by 68% YoY but it has decreased by 8% QoQ
The operating margin has grown by 50% YoY but it has contracted by 7% from the previous quarter

Growth

What is Hologic's growth rate over time

Valuation

What is Hologic stock price valuation
P/E
10.16
P/B
4.44
P/S
3.37
EV/EBIT
8.33
EV/EBITDA
7.15
EV/Sales
3.63
The EPS has surged by 72% year-on-year but it has declined by 7% since the previous quarter
The stock's price to earnings (P/E) is 5% less than its last 4 quarters average of 10.7
HOLX's equity has surged by 56% year-on-year and by 9% since the previous quarter
HOLX's price to book (P/B) is 11% lower than its 5-year quarterly average of 5.0 and 11% lower than its last 4 quarters average of 5.0
The revenue has grown by 49% YoY
HOLX's price to sales (P/S) is 9% lower than its 5-year quarterly average of 3.7 and 6% lower than its last 4 quarters average of 3.6

Efficiency

How efficient is Hologic business performance
HOLX's return on invested capital has surged by 103% year-on-year but it is down by 9% since the previous quarter
The return on sales is up by 47% year-on-year but it has declined by 7% since the previous quarter
Hologic's return on assets has increased by 38% YoY but it has decreased by 13% QoQ
The ROE has contracted by 17% from the previous quarter but it has grown by 2.9% YoY

Dividends

What is HOLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HOLX.

Financial health

How did Hologic financials performed over time
The total assets is 90% higher than the total liabilities
Hologic's current ratio has increased by 45% from the previous quarter and by 34% YoY
Hologic's quick ratio has increased by 31% QoQ and by 14% YoY
The company's debt is 28% lower than its equity
HOLX's equity has surged by 56% year-on-year and by 9% since the previous quarter
Hologic's debt to equity has decreased by 36% YoY and by 11% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.